Author

Yasuhiro Mihashi

Observed name: Y. Mihashi

Institutions: Toneyama National Hospital, National Hospital Organization

Observed institutions: Toneyama National Hospital, National Hospital Organization

ORCID: 0009-0007-7223-4542

Observed ORCID: 0009-0007-7223-4542

OpenAlex ID: A5093036491

Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study

2025 · Akihiro Tsukaguchi, Kinnosuke Matsumoto, et al. · European Journal of Cancer · 17

Diagnosis and Management of Drug-Induced Interstitial Lung Disease Associated with Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium Avium Complex Pulmonary Disease: A Case Report

2023 · Kazuki Hashimoto, Takuro Nii, et al. · Infection and Drug Resistance · 9

PDF

Gas exchange efficiency slopes to assess exercise tolerance in chronic obstructive pulmonary disease

2024 · Hiromi Yanagi, Keisuke Miki, et al. · BMC Pulmonary Medicine · 4

PDF

A Multicenter, Retrospective, Real-World Study of Atezolizumab Plus Chemotherapy and Pembrolizumab Plus Chemotherapy for Older Patients With NSCLC

2025 · Kensuke Kanaoka, Kinnosuke Matsumoto, et al. · JTO Clinical and Research Reports · 2

PDF

Impact of preexisting interstitial lung disease on pneumonitis and survival during first-line immune checkpoint inhibitor-based therapy in non-small cell lung cancer

2026 · Kinnosuke Matsumoto, Yuji Yamamoto, et al. · European Journal of Cancer · 1

PDF

Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non‐Squamous Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

2026 · Keijiro Yamauchi, Kinnosuke Matsumoto, et al. · Thoracic Cancer · 1

Exercise alveolar oxygen extraction rate reflects ventilatory efficiency and predicts outcomes in idiopathic pulmonary fibrosis

2025 · Keisuke Miki, Ryosuke Nishijima, et al. · BMC Pulmonary Medicine · 1

Multicenter retrospective study of selpercatinib treatment for advanced or recurrent RET fusion-positive non-small cell lung cancer in Japan

2025 · Yasuhiro Mihashi, Kiyohide Komuta, et al. · Investigational New Drugs · 1

Corrigendum to “Timing of first pembrolizumab infusion and long-term outcomes in non-small cell lung cancer: A retrospective multicenter study” [Eur J Cancer. 2025;228:115748]

2025 · Akihiro Tsukaguchi, Kinnosuke Matsumoto, et al. · European Journal of Cancer · 1

PDF

Exertional oxygen consumption ability reflects ventilatory efficiency and is a prognostic factor in idiopathic pulmonary fibrosis

2025 · Keisuke Miki, Ryosuke Nishijima, et al. · European Respiratory Journal · 1

1997P Comparative effectiveness of first-line MET tyrosine kinase inhibitors versus Immune checkpoint inhibitors with or without chemotherapy in advanced non-small cell lung cancer with MET exon 14 skipping mutation: A multicenter retrospective study in Japan

2025 · K. Komuta, K. Kunimasa, et al. · Annals of Oncology · 1

Exercise-induced Right-to-left Shunt in a Patient with Combined Pulmonary Fibrosis and Emphysema

2025 · Yasuhiro Mihashi, Keisuke Miki, et al. · Internal Medicine · 1

Increased Oxygen Consumption Ability With Pulmonary Rehabilitation Improves Submaximal Exercise Capacity in Advanced COPD

2025 · Hitoshi Sumitani, Keisuke Miki, et al. · Respiratory Care · 1

Exercise intolerance and oxygen dynamics in nontuberculous mycobacteria with bronchiectasis

2024 · Satoshi Miyamoto, Keisuke Miki, et al. · Respiratory Investigation · 1

Body positioning-related laryngeal narrowing pattern and expiratory mechanical constraints in advanced chronic obstructive pulmonary disease: A case report

2024 · Yuka Nagata, Keisuke Miki, et al. · Respiratory Investigation · 1

Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapy

2026 · Hirotomo Machiyama, Kinnosuke Matsumoto, et al. · Respiratory Medicine

Repotrectinib was effective for carcinomatous meningitis occurring during the treatment of early-generation ROS1 TKIs for ROS1 fusion-positive NSCLC: A case report

2026 · Yasuhiro Mihashi, Kenta Sugisawa, et al. · International Journal of Lung Cancer

Clinical Outcomes of First-Line Pembrolizumab Monotherapy in Advanced NSCLC With PD-L1 Tumor Proportion Score of 1% to 49%: A Retrospective Multicenter Study

2026 · Akito Miyazaki, Kinnosuke Matsumoto, et al. · JTO Clinical and Research Reports

PDF

Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study

2025 · Nao Shoshihara, Kinnosuke Matsumoto, et al. · Lung Cancer

PDF

P3.12.36 Multicenter Retrospective Study of Selpercatinib Treatment for Advanced or Recurrent RET Fusion-Positive NSCLC in Japan

2025 · Y. Mihashi · Journal of Thoracic Oncology

EP.17.25 The Transition of Treatment Choice for First-Line Treatment for Advanced or Recurrent NSCLC and the Patients’ Characteristics

2025 · Y. Akazawa, A. Kubota, et al. · Journal of Thoracic Oncology

EP.13B.12 Chemotherapy Sensitivity for Recurrent Small-Cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens

2024 · Y. Akazawa, A. Kubota, et al. · Journal of Thoracic Oncology

PDF

Works count: 22

Citation count: 43

H-index: 3

I10-index: 1